4.5 Article

Human Schwann Cells Retain Essential Phenotype Characteristics After Immortalization

Journal

STEM CELLS AND DEVELOPMENT
Volume 21, Issue 3, Pages 423-431

Publisher

MARY ANN LIEBERT, INC
DOI: 10.1089/scd.2010.0513

Keywords

-

Funding

  1. NIH [R01-NS43991]
  2. Adelson Medical Research Foundation
  3. German research foundation (DFG) [Le2368-1/1]

Ask authors/readers for more resources

Schwann cells (SCs) play an important role in the pathogenesis of peripheral nerve diseases and represent a potential target for development of therapies. However, use of primary human SCs (hSCs) for in vitro models is limited because these cells are difficult to prepare and maintain in high yield and purity under common cell culture conditions. To circumvent this obstacle, we immortalized primary human fetal SCs using the SV40 large T-antigen and human telomerase reverse transcriptase expression vectors. After cloning, selection, and purification, we evaluated several immortalized SC lines for their ability to express extracellular matrix (ECM) molecules and myelinate embryonic rat sensory axons. In addition, we established a gene expression profile and explored their sensitivity to oxidative stress in a simple in vitro assay. Immortalized hSC clones expressed common glial markers and a broad variety of growth factors, receptors, and ECM molecules as determined by immunocytochemistry, microarray, and quantitative reverse transcription polymerase chain reaction. In neuron-SC co-cultures, these cells were able to myelinate rat dorsal root ganglia neurons, although their effectiveness was lower in comparison to primary rat SCs. In toxicity assays, immortalized hSCs remain susceptible to oxidative stress induced by H2O2. This study shows that, using specific immortalization techniques, it is possible to establish hSC lines that retain characteristics of typical primary hSCs. These cells are particularly useful for drug screening and studies aimed at disease mechanisms involving SCs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Antibody response after COVID-19 vaccination in intravenous immunoglobulin-treated immune neuropathies

Martin K. R. Svacina, Anika Meissner, Finja Schweitzer, Anne Ladwig, Alina Sprenger-Svacina, Ines Klein, Hauke Wuestenberg, Felix Kohle, Christian Schneider, Nicolai B. Grether, Gilbert Wunderlich, Gereon R. Fink, Florian Klein, Veronica Di Cristanziano, Helmar C. Lehmann

Summary: The study found that IVIg does not impair the antibody response to COVID-19 mRNA vaccine and does not significantly alter serum anti-SARS-CoV-2 IgG titers.

EUROPEAN JOURNAL OF NEUROLOGY (2022)

Article Clinical Neurology

Electrodiagnostic subtyping in Guillain-Barre syndrome: Use of criteria in practice based on a survey study in IGOS

Samuel Arends, Judith Drenthen, Peter Y. K. van den Bergh, Robert D. M. Hadden, Nortina Shahrizaila, Mazen M. Dimachkie, Gerardo Gutierrez Gutierrez, Hans Katzberg, Lynette Kiers, Helmar C. Lehmann, Yann Pereon, Ricardo C. Reisin, Antonino Uncini, Camiel Verhamme, Wagar Waheed, David R. Cornblath, Bart C. Jacobs

Summary: This study investigated how neuromuscular EDx experts approach key aspects of GBS subtyping in practice and compared previously published EDx criteria for GBS. The study found extensive variability in the practical use of EDx criteria, potentially reducing the reproducibility of GBS subtyping.

JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2022)

Article Clinical Neurology

Neuromuscular manifestations in long-COVID syndrome

Helmar C. Lehmann

Summary: Long-COVID syndrome refers to symptoms that occur after SARS-CoV-2 infections and persist for several weeks. This review article summarizes the data on neuromuscular manifestations of long-COVID and points out the limited evidence available so far.

NERVENARZT (2022)

Article Clinical Neurology

Amyloidogenicity assessment of transthyretin gene variants

Nicolai B. Grether, Felix Napravnik, Thomas Imhof, Reinhold P. Linke, Jan H. Brasen, Jessica Schmitz, Maike Dohrn, Christian Schneider, Martin K. R. Svacina, Jorg Stetefeld, Manuel Koch, Helmar C. Lehmann

Summary: The objective of this study was to assess the amyloidogenic potential of variants of uncertain significance in vitro. Results showed that transthyretin-Ala65Val had significantly higher amyloidogenic potential compared to wild-type transthyretin, while the other eight variants did not show increased amyloidogenic potential. The combination of three assays and histopathology confirmed the amyloidogenicity of transthyretin-Ala65Val.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2022)

Article Clinical Neurology

MRI correlates of motoneuron loss in SMA

Alina Sprenger-Svacina, Johannes Haensch, Kilian Weiss, Nils Grosse Hokamp, David Maintz, Marc Schlamann, Gereon R. Fink, Natalie Schloss, Kai Laukamp, Gilbert Wunderlich, Helmar C. Lehmann, Thorsten Lichtenstein

Summary: This study evaluated the utility of a multi-parametric MRI protocol to detect loss of spinal motor neurons and subsequent muscle damage in adult SMA patients. The results showed that water T-2 mapping and Dixon-based PDFF estimation can distinguish between SMA patients and controls.

JOURNAL OF NEUROLOGY (2023)

Article Clinical Neurology

Public health situation of CIDP patients in nine German centers-neuritis network Germany

Anna Lena Fisse, Jeremias Motte, Thomas Grueter, Felix Kohle, Cornelius Kronlage, Jan-Hendrik Stahl, Natalie Winter, Tabea Seeliger, Stefan Gingele, Frauke Stascheit, Benjamin Hotter, Juliane Klehmet, Karsten Kummer, Elena K. Enax-Krumova, Dietrich Sturm, Thomas Skripuletz, Jens Schmidt, Min-Suk Yoon, Kalliopi Pitarokoili, Helmar C. Lehmann, Alexander Grimm

Summary: This study investigates the current care of patients with immune-mediated polyneuropathies in specialized centers in Germany and provides important epidemiological insights. The findings suggest that the development of specific treatment and follow-up recommendations is necessary to ensure a uniform standard of patient care.

NERVENARZT (2023)

Biographical-Item Clinical Neurology

In Memoriam: Daniel B. Drachman

Justin C. McArthur, Klaus Toyka, Ahmet Hoke

ANNALS OF NEUROLOGY (2023)

Article Clinical Neurology

The gut microbiome in intravenous immunoglobulin-treated chronic inflammatory demyelinating polyneuropathy

Martin K. R. Svacina, Alina Sprenger-Svacina, Anastasia Tsakmaklis, Alina M. Rueb, Ines Klein, Hauke Wuestenberg, Gereon R. Fink, Helmar C. Lehmann, Maria J. G. T. Vehreschild, Fedja Farowski

Summary: This study found that the gut microbiome of CIDP patients has increased diversity and enrichment of Firmicutes, which produce short-chain fatty acids. However, intravenous immunoglobulin (IVIg) administration did not have a short-term impact on the gut microbiome in CIDP patients.

EUROPEAN JOURNAL OF NEUROLOGY (2023)

Editorial Material Clinical Neurology

Change of guard at ACTN

Ahmet Hoke

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

Article Clinical Neurology

Downregulation of SF3B2 protects CNS neurons in models of multiple sclerosis

Ye Eun Jeong, Labchan Rajbhandari, Byung Woo Kim, Arun Venkatesan, Ahmet Hoke

Summary: Objective: Neurodegeneration induced by inflammatory stress in multiple sclerosis (MS) leads to long-term neurological disabilities that are not amenable to current immunomodulatory therapies. Methods and Results: This study found that neuronal downregulation of Splicing factor 3b subunit 2 (SF3B2) preserves retinal ganglion cell (RGC) survival and axonal integrity in experimental autoimmune encephalomyelitis (EAE)-induced mice. The downregulation of SF3B2 prevents activation of Sterile Alpha and TIR Motif Containing 1 (Sarm1), a key enzyme that mediates programmed axon degeneration. Interpretation: The downregulation of SF3B2 is a novel potential therapeutic target to prevent secondary neurodegeneration in MS.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

Article Neurosciences

CIDP: Analysis of Immunomarkers During COVID-19 mRNA-Vaccination and IVIg-Immunomodulation: An Exploratory Study

Martin K. R. Svacina, Anika Meissner, Finja Schweitzer, Alina Sprenger-Svacina, Ines Klein, Hauke Wuestenberg, Felix Kohle, Helene L. Walter, Michael Schroeter, Helmar C. Lehmann

Summary: This exploratory study analyzed the impact of COVID-19 mRNA vaccine on disease activity and IVIg-immunomodulation in CIDP patients. The results showed that except for a significantly lower expression of CD32b on naive B cells after vaccination, there were no significant alterations in immunomarkers for CIDP or IVIg-mediated immunomodulation. This study suggests that COVID-19 mRNA vaccine does not affect immune activity in CIDP and does not alter the immunomodulatory effects of IVIg.

JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2023)

Review Clinical Neurology

Axonal degeneration in chemotherapy-induced peripheral neurotoxicity: clinical and experimental evidence

Susanna B. Park, Aysel Cetinkaya-Fisgin, Andreas A. Argyriou, Ahmet Hoeke, Guido Cavaletti, Paola Alberti

Summary: Multiple mechanisms contribute to chemotherapy-induced peripheral neurotoxicity (CIPN), including axonal degeneration. This review integrates evidence from preclinical and clinical studies to examine the triggers and molecular pathways involved in axonal degeneration in CIPN, with a focus on the SARM1-mediated pathway. Potential clinical markers of axonal dysfunction are discussed, along with potential treatment strategies to intervene in axonal degeneration. Understanding the processes underlying axonal degeneration in CIPN will have broader implications for the development and progression of axonal dysfunction, and may lead to successful interventions for CIPN and other neurodegenerative disorders.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Cell Biology

Glycyrrhizic Acid Prevents Paclitaxel-Induced Neuropathy via Inhibition of OATP-Mediated Neuronal Uptake

Ines Klein, Jorg Isensee, Martin H. J. Wiesen, Thomas Imhof, Meike K. Wassermann, Carsten Mueller, Tim Hucho, Manuel Koch, Helmar C. Lehmann

Summary: Peripheral neuropathy is a common side effect of cancer treatment with paclitaxel, but the mechanisms of paclitaxel transport into neurons are not well understood. This study identified OATP1A1 and OATP1B2 as the primary neuronal transporters for paclitaxel and suggested that inhibiting these transporters may prevent paclitaxel-induced neuropathy.

CELLS (2023)

Article Medicine, Research & Experimental

Senescent Schwann cells induced by aging and chronic denervation impair axonal regeneration following peripheral nerve injury

Andres Fuentes-Flores, Cristian Geronimo-Olvera, Karina Girardi, David Necunir-Ibarra, Sandip Kumar Patel, Joanna Bons, Megan C. Wright, Daniel Geschwind, Ahmet Hoke, Jose A. Gomez-Sanchez, Birgit Schilling, Daniela L. Rebolledo, Judith Campisi, Felipe A. Court

Summary: Reparative Schwann cells transition into a senescent phenotype in aging and chronic denervation, leading to inhibition of axonal regeneration. Elimination of senescent cells improves nerve regeneration and functional recovery.

EMBO MOLECULAR MEDICINE (2023)

Review Clinical Neurology

Repurposing MS immunotherapies for CIDP and other autoimmune neuropathies: unfulfilled promise or efficient strategy?

Felix Kohle, Marinos C. C. Dalakas, Helmar C. C. Lehmann

Summary: Despite advances in the treatment of CIDP and other AN, many patients remain unsatisfied with available treatments. Repurposing DMTs from other autoimmune conditions, particularly MS and NMOSD, is a promising strategy for establishing new treatment options for AN. B cell-directed and complement-targeting strategies, such as anti-CD20/anti-CD19 agents, Bruton's tyrosine kinase inhibitors, and anti-C5 agents, show promise as therapeutic approaches for AN.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2023)

No Data Available